$FTRE

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.

Fortrea Holdings (FTRE) reported stronger biotech demand, a backlog of about $7.8B, and raised full-year 2026 revenue and adjusted EBITDA guidance, drawing renewed investor attention. Shares last closed at $18.43, up 4.18% on the day and 19.44% over 90 days. Simply Wall St cites a $17.25 fair value estimate and notes other valuation models.

Argus on Aug. 5, 2026 lowered its target price for Fortrea Holdings Inc. (FTRE) to $19.00. Fortrea is described as a global contract research organization providing late-stage clinical trial management and related services, including phases 1 through 4.

Thakral Anshul (Chief Executive Officer) sold 111,857 shares of Fortrea Holdings Inc. (FTRE) at an average of $18.12 ($18.06–$18.17, $2.03M total) across 2 trades on 2026-08-06.

Thakral Anshul (Chief Executive Officer) sold 99,869 shares of Fortrea Holdings Inc. (FTRE) at an average of $19.16 ($19.03–$19.28, $1.91M total) across 2 trades on 2026-08-05.

SANDERS MACHELLE sold 9,700 shares of Fortrea Holdings Inc. (FTRE) at $18.01 ($0.17M total) on 2026-08-03.

The article says investors are rotating from highly valued AI infrastructure toward healthcare, citing a Bank of America survey and recent sector performance. It highlights three healthcare stocks: Aurinia Pharmaceuticals (AUPH) with Q1 revenue $77.7M and EPS $0.25; Fortrea (FTRE) raising full-year sales and adjusted EBITDA; and Aveanna (AVAH) after a $175.5M acquisition, guiding FY revenue $2.63B-$2.65B.

"The environment has become more supportive, but our results are not simply the result of market recovery," Thakral said, attributing the performance to changes in commercial execution, including improved global coordination, a sharper focus on opportunities where the company can compete effectively and a clearer approach to serving distinct customer segments. Thakral said Fortrea's clinical pharmacology services business was a particular area of strength.

Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 revenue of $678.2 million, down 4.5% year over year but 4.7% above market expectations, according to the company. Full-year revenue guidance was $2.66 billion at the midpoint, 1.8% above analysts’ estimates. Non-GAAP EPS was $0.23, 27.2% above consensus.

Fortrea (Nasdaq: FTRE) reported Q2 2026 revenue of $678.2 million, down from $710.3 million a year earlier. GAAP net loss was $13.2 million, while adjusted net income was $22.7 million and adjusted EBITDA $58.7 million. Book-to-bill was 1.06x and backlog $7.8 billion. Full-year guidance was raised to $2.62B-$2.69B revenue and $205M-$220M adjusted EBITDA.